@article{oai:niigata-u.repo.nii.ac.jp:00022677,
 author = {伊藤, 聡 and 藤原, 道夫 and 荒川, 正昭},
 issue = {12},
 journal = {新潟医学会雑誌, 新潟医学会雑誌},
 month = {Dec},
 note = {The therapeutic effect of 15－deoxyspergualin (DSP), a newly developed immunosuppressive agent, on the development of spontaneously occuring lupus glomerulonephritis in MRL/1pr and male BXSB mice was examined. Administration of the drug was begun from the age of 13 weeks, when polyclonal B cell activation and lupus nephropathy were apparent. Treatment with DSP up to 20 weeks of age at a dose of 2mg/kg twice a day, 5mg/kg daily or 20mg/kg three times a week strongly suppressed the increment of IgG-producing cell numbers in the spleen, and decreased serum levels of immune complexes and anti-DNA antibodies. Glomerular histological score by light microscopy and IgG and C3 deposition estimated by immunofluorescence were remarkably improved. In MRL/1pr mice, DSP reduced the swelling of lymph node and the numbers of Thy-1^+, B220^+ cell population in lymphoid organs. Responsiveness to Con A and IL-2 production of spleen cells were improved by the treatment. Thus, DSP was shown to suppress the progression of polyclonal B cell activation and lupus nephropathy in MRL/1pr and male BXSB mice. These results suggest that DSP might be used as a therapeutic agent for human erythematosus.},
 pages = {977--982},
 title = {4) エリテマトーデスの治療モデル(シンポジウム 自己免疫疾患, 第445回新潟医学会)},
 volume = {103},
 year = {1989}
}